Clinical trial
A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults
NCT00563134 is registered in ClinicalTrials.gov with Hospital Authority, Hong Kong as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults
- Lead sponsor
- Hospital Authority, Hong Kong
- Phase
- Not applicable
- Overall status
- Suspended
- Start date
- October 31, 2005
- Completion date
- December 31, 2006
- Enrollment
- 1,800 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.